Avalo Therapeutics, Inc. (AVTX): R&D Expense
$50.08M
Year ended 2025-12-31
$64.36M
Trailing 12 months to 2026-06-30
+17.0%
3-year compound annual growth
+9.2%
5-year compound annual growth
+22.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.08M | +105.0% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $24.44M | +77.3% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $13.78M | -56.0% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $31.31M | -47.7% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $59.84M | +85.9% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $32.19M | +173.7% | 2022-03-02, From 2020-01-01 |
| 2019-12-31 | $11.76M | +103.3% | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | $5.79M | +32.3% | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $4.37M | -56.9% | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | $10.15M | +54.1% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $6.59M | -46.2% | 2018-04-02, From 2015-01-01 |
| 2014-12-31 | $12.24M | +37.3% | 2017-03-14, From 2014-01-01 |
| 2013-12-31 | $8.91M | n/a | 2016-03-23, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $37.80M | +29.2% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $5.44M | -14.8% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $54.21M | -28.3% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $10.75M | -16.6% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $21.12M | -29.7% |
Compare AVTX, CNTB, HCWB, INO side by side · Screen every company in Pharmaceutical Preparations ↗